Fonte: Il Messaggero
American volunteers test the vaccine
While the novel coronavirus Covid-19 keeps spreading, and the first clinical trial has begun in the Kaiser Permanente Washington Research Institute of Seattle, many companies are working on a vaccine, and Italy is at the forefront. We are talking about a joint venture between the Jenner Institute of the Oxford University and Advent Srl, the GMP-certified Contract Development and Manufacturing Organization of IRBM Group, located in Pomezia, Rome. The key to success of the Italian “candidate” could be the expertise of the two partners. The Jenner Institute is expert in surface antigens –called “Spike”, which are being largely studied in the coronavirus field. On the other hand Advent has already used an adenovirus platform widely. Pietro Di Lorenzo, President and CEO of IRBM, CEO of Advent and CNCCS, explains why the candidate vaccine works like a “chimera” for the coronavirus.
Article by Francesca Cerati and Federico Mereta published on Il Sole 24 Ore Salute – 17/03/2020